IBKS No2 SPAC (204840) - Total Liabilities

Latest as of March 2026: ₩28.80 Billion KRW ≈ $19.52 Million USD

Based on the latest financial reports, IBKS No2 SPAC (204840) has total liabilities worth ₩28.80 Billion KRW (≈ $19.52 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see how large is IBKS No2 SPAC's balance sheet.

IBKS No2 SPAC - Total Liabilities Trend (2015–2025)

This chart illustrates how IBKS No2 SPAC's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of IBKS No2 SPAC to see how much of total assets are deployed in long-term investments.

IBKS No2 SPAC Competitors by Total Liabilities

The table below lists competitors of IBKS No2 SPAC ranked by their total liabilities.

Company	Country	Total Liabilities
Rama Phosphates Limited NSE:RAMAPHO	India	Rs2.41 Billion
Full Wang International Development Co Ltd TWO:6219	Taiwan	NT$11.84 Billion
Anson Resources Limited F:9MY	Germany	€3.71 Million
Dae Won Chem KO:024890	Korea	₩103.81 Billion
Tinka Resources Limited V:TK	Canada	CA$598.97K
RYTHM, Inc. NASDAQ:RYM	USA	$96.29 Million
Dae Young Pkg KO:014160	Korea	₩72.47 Billion
Hilbert Group AB Series B ST:HILB-B	Sweden	Skr232.20 Million

Liability Composition Analysis (2015–2025)

This chart breaks down IBKS No2 SPAC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check IBKS No2 SPAC liquidity resilience to evaluate the company's liquid asset resilience ratio.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.45	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.59	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how IBKS No2 SPAC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for IBKS No2 SPAC (2015–2025)

The table below shows the annual total liabilities of IBKS No2 SPAC from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩28.90 Billion ≈ $19.58 Million	+26.89%
2024-12-31	₩22.77 Billion ≈ $15.43 Million	-17.45%
2023-12-31	₩27.59 Billion ≈ $18.69 Million	+11.40%
2022-12-31	₩24.76 Billion ≈ $16.78 Million	+64.59%
2021-12-31	₩15.05 Billion ≈ $10.20 Million	-27.07%
2020-12-31	₩20.63 Billion ≈ $13.98 Million	-14.70%
2019-12-31	₩24.19 Billion ≈ $16.39 Million	+1.86%
2018-12-31	₩23.74 Billion ≈ $16.09 Million	+161.34%
2017-12-31	₩9.09 Billion ≈ $6.16 Million	+140.17%
2016-12-31	₩3.78 Billion ≈ $2.56 Million	-33.42%
2015-12-31	₩5.68 Billion ≈ $3.85 Million	--

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$48.40 Million

₩71.42 Billion KRW

Market Cap Rank

#22144 Global

#1375 in Korea

Share Price

₩4605.00

Change (1 day)

+0.77%

52-Week Range

₩780.00 - ₩4605.00

All Time High

₩8655.23